The present study reports an explorative evaluation of a biofluid-based staging system for CSF and blood using three different tau fluid markers (p-tau217, p-tau205 and NTA-tau) as representative markers of early, intermediate and advanced AD, respectively [12, 39]. Here, MAPT is linked to Alzheimer disease.